News
Medesis Pharma signs a partnership with Partner International, world leader in transactions between biotechs and pharmaceutical laboratories
April, 2023
Medesis pharma sets up bond financing for a potential maximum nominal amount of 2,500,000 euros
March, 2023
New patent filed protecting the technical optimization of the Aonys microemulsion and its efficacy applied for all water-soluble pharmaceutical active ingredients
March, 2023
AONYS®, a unique platform for drug administration
AONYS® is a micro-emulsion for buccal administration, invisible to immune system and protected transport in HDL lipoproteins, allowing intracellular release with passage across the blood–brain barrier.
Our Goals
Medesis Pharma is a clinical-stage Pharmaceutical Biotechnology company developing innovative technology (AONYS®) for the delivery of therapeutic molecules to treat diseases with no current efficacious treatment.
Neurodegenerative diseases
Virology
